Reagila

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
07-06-2022
Ciri produk Ciri produk (SPC)
07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
18-09-2017

Bahan aktif:

cariprazine hydrochloride

Boleh didapati daripada:

Gedeon Richter

Kod ATC:

N05AX15

INN (Nama Antarabangsa):

cariprazine

Kumpulan terapeutik:

Psycholeptics

Kawasan terapeutik:

Schizophrenia

Tanda-tanda terapeutik:

Reagila is indicated for the treatment of schizophrenia in adult patients.

Ringkasan produk:

Revision: 7

Status kebenaran:

Authorised

Tarikh kebenaran:

2017-07-13

Risalah maklumat

                                40
B. PACKAGE LEAFLET
41
PACKAGE LEAFLET: INFORMATION FOR THE USER
REAGILA 1.5 MG HARD CAPSULES
REAGILA 3 MG HARD CAPSULES
REAGILA 4.5 MG HARD CAPSULES
REAGILA 6 MG HARD CAPSULES
cariprazine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Reagila is and what it is used for
2.
What you need to know before you take Reagila
3.
How to take Reagila
4.
Possible side effects
5.
How to store Reagila
6.
Contents of the pack and other information
1.
WHAT REAGILA IS AND WHAT IT IS USED FOR
Reagila contains the active substance cariprazine and belongs to a
group of medicines called
antipsychotics. It is used to treat adults with schizophrenia.
Schizophrenia is a disease characterised by symptoms such as hearing,
seeing or sensing things which
are not there (hallucination), suspiciousness, mistaken beliefs,
incoherent speech and behaviour and
emotional flatness. People with this condition may also feel
depressed, guilty, anxious, tense, or not
being able to start or keep up planned activities, unwillingness to
speak, lack of emotional response to
a situation that would normally stimulate feelings in others.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE REAGILA
DO NOT TAKE REAGILA
-
if you are allergic to cariprazine or any of the other ingredients of
this medicine (listed in
section 6).
-
if you are taking medicines used to treat:
-
hepatitis caused by the hepatitis C virus (medicines containing
boceprevir and telaprevir)
-
bacterial infections (medicines containing clarithromycin,
telithromycin, erythromycin
and nafcillin)
-

                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Reagila 1.5 mg hard capsules
Reagila 3 mg hard capsules
Reagila 4.5 mg hard capsules
Reagila 6 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Reagila 1.5 mg hard capsules
Each hard capsule contains cariprazine hydrochloride corresponding to
1.5 mg cariprazine.
Reagila 3 mg hard capsules
Each hard capsule contains cariprazine hydrochloride corresponding to
3 mg cariprazine.
Excipient with known effect
Each hard capsule contains 0.0003 mg Allura red AC (E 129).
Reagila 4.5 mg hard capsules
Each hard capsule contains cariprazine hydrochloride corresponding to
4.5 mg cariprazine.
Excipient with known effect
Each hard capsule contains 0.0008 mg Allura red AC (E 129).
Reagila 6 mg hard capsules
Each hard capsule contains cariprazine hydrochloride corresponding to
6 mg cariprazine.
Excipient with known effect
Each hard capsule contains 0.0096 mg Allura red AC (E 129).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule
Reagila 1.5 mg hard capsules
‘Size 4’ (approximately 14.3 mm in length) hard gelatin capsule
with white opaque cap and white
opaque body imprinted with “GR 1.5” on the capsule body with black
ink. The capsules are filled with
white to yellowish white powder mixture.
Reagila 3 mg hard capsules
‘Size 4’ (approximately 14.3 mm in length) hard gelatin capsule
with green opaque cap and white
opaque body imprinted with “GR 3” on the capsule body with black
ink. The capsules are filled with
white to yellowish white powder mixture.
3
Reagila 4.5 mg hard capsules
‘Size 4’ (approximately 14.3 mm in length) hard gelatin capsule
with green opaque cap and green
opaque body imprinted with “GR 4.5” on the capsule body with white
ink. The capsules are filled with
white to yellowish white powder mixture.
Reagila 6 mg hard capsules
‘Size 3’ (approximately 15.9 mm in length) hard gelatin capsule
with purple opaque cap and white
opaque body imprinted with “GR 6” on th
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 07-06-2022
Ciri produk Ciri produk Bulgaria 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 18-09-2017
Risalah maklumat Risalah maklumat Sepanyol 07-06-2022
Ciri produk Ciri produk Sepanyol 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 18-09-2017
Risalah maklumat Risalah maklumat Czech 07-06-2022
Ciri produk Ciri produk Czech 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Czech 18-09-2017
Risalah maklumat Risalah maklumat Denmark 07-06-2022
Ciri produk Ciri produk Denmark 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 18-09-2017
Risalah maklumat Risalah maklumat Jerman 07-06-2022
Ciri produk Ciri produk Jerman 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 18-09-2017
Risalah maklumat Risalah maklumat Estonia 07-06-2022
Ciri produk Ciri produk Estonia 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 18-09-2017
Risalah maklumat Risalah maklumat Greek 07-06-2022
Ciri produk Ciri produk Greek 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Greek 18-09-2017
Risalah maklumat Risalah maklumat Perancis 07-06-2022
Ciri produk Ciri produk Perancis 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 18-09-2017
Risalah maklumat Risalah maklumat Itali 07-06-2022
Ciri produk Ciri produk Itali 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Itali 18-09-2017
Risalah maklumat Risalah maklumat Latvia 07-06-2022
Ciri produk Ciri produk Latvia 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 18-09-2017
Risalah maklumat Risalah maklumat Lithuania 07-06-2022
Ciri produk Ciri produk Lithuania 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 18-09-2017
Risalah maklumat Risalah maklumat Hungary 07-06-2022
Ciri produk Ciri produk Hungary 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 18-09-2017
Risalah maklumat Risalah maklumat Malta 07-06-2022
Ciri produk Ciri produk Malta 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Malta 18-09-2017
Risalah maklumat Risalah maklumat Belanda 07-06-2022
Ciri produk Ciri produk Belanda 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 18-09-2017
Risalah maklumat Risalah maklumat Poland 07-06-2022
Ciri produk Ciri produk Poland 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Poland 18-09-2017
Risalah maklumat Risalah maklumat Portugis 07-06-2022
Ciri produk Ciri produk Portugis 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 18-09-2017
Risalah maklumat Risalah maklumat Romania 07-06-2022
Ciri produk Ciri produk Romania 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Romania 18-09-2017
Risalah maklumat Risalah maklumat Slovak 07-06-2022
Ciri produk Ciri produk Slovak 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 18-09-2017
Risalah maklumat Risalah maklumat Slovenia 07-06-2022
Ciri produk Ciri produk Slovenia 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 18-09-2017
Risalah maklumat Risalah maklumat Finland 07-06-2022
Ciri produk Ciri produk Finland 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Finland 18-09-2017
Risalah maklumat Risalah maklumat Sweden 07-06-2022
Ciri produk Ciri produk Sweden 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 18-09-2017
Risalah maklumat Risalah maklumat Norway 07-06-2022
Ciri produk Ciri produk Norway 07-06-2022
Risalah maklumat Risalah maklumat Iceland 07-06-2022
Ciri produk Ciri produk Iceland 07-06-2022
Risalah maklumat Risalah maklumat Croat 07-06-2022
Ciri produk Ciri produk Croat 07-06-2022
Laporan Penilaian Awam Laporan Penilaian Awam Croat 18-09-2017

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen